A single-arm, multi-center study of Sacituzumab Tirumotecan (Sac-TMT) plus Tagitanlimab as first-line therapy for KRAS-mutated advanced NSCLC (ChiCTR) - Oct 16, 2026 - P=N/A | N=54 | Not yet recruiting | Sponsor: Shanghai Chest Hospital; Shanghai Chest Hospital
New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • KRAS • ROS1
|